EVALUATION AND ASSESSMENT OF ADVERSE DRUG REACTIONS DEVELOPED USING NEWLY PRESCRIBED DRUGS IN PATIENTS WITH ACUTE DISEASE

The objective of current research is to assess the type of Adverse Drug Reactions (ADR) and associated risk factors, assess the prevalence, estimate the incidence of serious and fatal ADR and the severity of ADRs based on data collected from patients with ADRs caused by drug initially prescribed. Data of patients with acute diseases were collected and analyzed using SAS version 9.1. About 252 ADRs were identified among 183 patients. The majority of patients (70.49%) experienced one ADR reaction per patient. A higher risk of ADR was observed in the age group of 41-50 yrs (33.33%). The prevalence of ADR is predominant in adults (82.51%). ADR incidents were higher in gastrointestinal reactions (26.19%), with most of them identified by doctors or prescribers (44.41%). Suspected drug was withdrawn in 57.92% cases, specific and symptomatic treatment given to 45.23% followed by only symptiotic treatment for 30.95%. Definite improvement was predominant in challenged patients, whereas recurrence of symptoms was significantly observed among rechallenged patients with the respective suspected drug. According to the WHO probability scale and Naronj’s scale, the causality assessment of ADRs indicates that possible and probable reactions were statistically significant. In 252 ADRs cases, 50% reactions predictable and 50% reactions were not-predictable. The study concluded that ADRs in patients with acute diseases are common and are preventable by spontaneous reporting of ADRs, proper documentation, and periodic reporting to regional pharmacovigilance centers to ensure drug safety.